Acoustically-Gated Autonomous Therapeutics (AGAT): Wave-Native Zwitterionic Delivery for Localized Gastrointestinal Immunomodulation

The Acoustically‑Gated Autonomous Therapeutics (AGAT) framework is an in silico conceptual architecture engineered to overcome the systemic‑toxicity ceiling that limits current treatments for Crohn’s disease and Inflammatory Bowel Disease (IBD). AGAT separates delivery from drug action by using a mechanically gated trigger to achieve hyper‑localized immunomodulation directly at inflamed mucosal surfaces. Its therapeutic payload, Vaporix‑23 (VX‑23), is a de novo synthetic peptide optimized for IL‑23 receptor antagonism and intentionally designed with mechanically gated fragility: if VX‑23 escapes into systemic circulation after release, its rapid plasma‑driven degradation neutralizes activity within minutes, eliminating the risk of broad immunosuppression. To ensure zero‑leakage transit through the gastrointestinal tract, VX‑23 is encapsulated within a pH‑resistant, zwitterionic block‑copolymer matrix seeded with biologically inert perfluorocarbon (PFC) nanodroplets. This composite shell remains structurally absolute under physiological conditions until exposed to a 1.2 MHz focused acoustic field. At the target site, the acoustic energy initiates Acoustic Droplet Vaporization (ADV), driving an instantaneous liquid‑to‑gas phase transition within the PFC inclusions. The resulting volumetric expansion generates intense internal pressure, fracturing the zwitterionic lattice from within and releasing 100% of the payload directly onto the intended mucosal tissue. Clinically, AGAT is paired with a wearable Acoustic Phased Array Transducer (APAT) capable of dynamically steering and focusing acoustic energy through visceral tissue to exceed the vaporization threshold only at the prescribed depth. A dedicated Frequency‑Encoded Elastic Network (FEEN) digital twin models tissue attenuation, ensuring both precision and safety across patient‑specific anatomies. After deployment, the shattered polymer fragments and dissipated PFC gas remain confined to the GI lumen and are cleared naturally via motility, fulfilling AGAT’s central promise: a zero‑toxicity, zero‑systemic‑exposure therapeutic pipeline.